This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Hansen Medical, Inc. (
Q4 2010 Earnings Call
February 23, 2011 05:00 pm ET
Matt Clawson – Investor Relations, Allen & Caron Inc.
Bruce Barclay – President and Chief Executive Officer
Peter Osborne – Interim Chief Financial Officer
Tim Lee – Piper Jaffray Roche
David Lewis -- Morgan Stanley
Good afternoon, ladies and gentlemen, thank you for standing by. Welcome to the Hansen Medical fourth quarter and year end conference call. During today’s presentation, all parties will be in a listen-only mode. Following the presentation, the conference will be opened for questions. (Operator instructions)
I would now like to turn the conference over to our host Mr. Matt Clawson, with Allen & Caron. Please go ahead sir.
Thank you, Jeremy. Good afternoon, everyone. Welcome to Hansen Medical’s 2010 fourth quarter and yearend results conference call. With us today are Hansen Medical’s President and CEO, Bruce Barclay; and the Company’s Interim Chief Financial Officer, Peter Osborne.
Before I turn the call over to management, please remember that our prepared remarks and responses to questions will contain forward-looking statements that are subject to a number of risks and uncertainties, the examples of such statements include statements about the expectations for commercializing our vascular roboting system, and the fossil technology, expectations regarding procedure and shipment trends, expectations round operating expense levels and the sufficiency of cash to support the launch of the next generation flexible catheter robotic flexible technology, important factors that could cause actual results may differ materially from those indicated by forward looking statements include, among others, that the development of new products and applications of technology are subject to design, engineering, manufacture challenges that could delays and uncertain timelines, costs, and results of clinical studies and of development.